Phase 2a, Single Center, Randomized, Double-blind, Study to Evaluate the Immunogenicity and Safety of One Single Administration of OVX836 Influenza Vaccine at Two Dose Levels (180??g or 480??g) Given Intramuscularly (IM), Either as a Booster or a Primary Vaccination in Healthy Subjects (Aged 20-69 Years) Previously Administered With OVX836 (90??g to 480??g), Influvac Tetra® or Placebo in the OVX836-002 (EudraCT Number: 2019-002939-28) and OVX836-003 (EudraCT Number: 2021-002535-39) Studies
Latest Information Update: 05 Sep 2024
At a glance
- Drugs OVX-836 (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors OSIVAX
- 05 Sep 2024 New trial record